APLS logo

Apellis Pharmaceuticals, Inc. (APLS) EBITDA

annual EBITDA:

-$154.53M+$340.60M(+68.79%)
December 31, 2024

Summary

  • As of today (September 16, 2025), APLS annual EBITDA is -$154.53 million, with the most recent change of +$340.60 million (+68.79%) on December 31, 2024.
  • During the last 3 years, APLS annual EBITDA has risen by +$576.74 million (+78.87%).
  • APLS annual EBITDA is now -3740.83% below its all-time high of -$4.02 million, reached on December 31, 2013.

Performance

APLS EBITDA Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Range

Earnings dates

OtherAPLSincome statement metrics

quarterly EBITDA:

-$32.84M+$50.04M(+60.38%)
June 30, 2025

Summary

  • As of today (September 16, 2025), APLS quarterly EBITDA is -$32.84 million, with the most recent change of +$50.04 million (+60.38%) on June 30, 2025.
  • Over the past year, APLS quarterly EBITDA has dropped by -$3.85 million (-13.26%).
  • APLS quarterly EBITDA is now -125.18% below its all-time high of $130.40 million, reached on December 31, 2020.

Performance

APLS quarterly EBITDA Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Range

Earnings dates

OtherAPLSincome statement metrics

TTM EBITDA:

-$188.26M-$3.85M(-2.09%)
June 30, 2025

Summary

  • As of today (September 16, 2025), APLS TTM EBITDA is -$188.26 million, with the most recent change of -$3.85 million (-2.09%) on June 30, 2025.
  • Over the past year, APLS TTM EBITDA has increased by +$123.08 million (+39.53%).
  • APLS TTM EBITDA is now -6958.94% below its all-time high of -$2.67 million, reached on September 30, 2014.

Performance

APLS TTM EBITDA Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Range

Earnings dates

OtherAPLSincome statement metrics

EBITDA Formula

EBITDA = Net Income + Interest + Taxes + Depreciation + Amortization

APLS EBITDA Trends

PeriodPeriodAnnualAnnualQuarterlyQuarterlyTTMTTM
1 y1 year+68.8%-13.3%+39.5%
3 y3 years+78.9%+77.8%+61.9%
5 y5 years+48.3%+71.5%+51.7%

APLS EBITDA Highs & Lows

PeriodPeriodAnnual vs highAnnual vs highAnnual vs lowAnnual vs lowQuarter. vs highQuarter. vs highQuarter. vs lowQuarter. vs lowTTM vs highTTM vs highTTM vs lowTTM vs low
3 y3-yearat high+78.9%-27.7%+81.2%-15.4%+70.5%
5 y5-yearat high+78.9%-125.2%+83.1%-15.4%+70.5%
alltimeall time-3740.8%+78.9%-125.2%+83.1%-6958.9%+70.5%

APLS EBITDA History

DateAnnualQuarterlyTTM
Jun 2025
-
-$32.84M(-60.4%)
-$188.26M(+2.1%)
Mar 2025
-
-$82.88M(+222.3%)
-$184.42M(+13.0%)
Dec 2024
-$154.53M(-68.8%)
-$25.72M(-45.1%)
-$163.18M(-26.3%)
Sep 2024
-
-$46.82M(+61.5%)
-$221.49M(-28.9%)
Jun 2024
-
-$28.99M(-53.0%)
-$311.34M(-22.6%)
Mar 2024
-
-$61.65M(-26.6%)
-$402.38M(-21.9%)
Dec 2023
-$495.13M(-19.8%)
-$84.03M(-38.5%)
-$515.42M(-13.4%)
Sep 2023
-
-$136.68M(+13.9%)
-$595.01M(-2.6%)
Jun 2023
-
-$120.03M(-31.3%)
-$610.92M(-4.4%)
Mar 2023
-
-$174.68M(+6.8%)
-$639.17M(+7.8%)
Dec 2022
-$617.33M(-15.6%)
-$163.63M(+7.2%)
-$593.13M(+14.4%)
Sep 2022
-
-$152.58M(+2.9%)
-$518.52M(+5.0%)
Jun 2022
-
-$148.28M(+15.3%)
-$493.66M(-8.4%)
Mar 2022
-
-$128.64M(+44.5%)
-$539.22M(+0.8%)
Dec 2021
-$731.27M(+134.2%)
-$89.02M(-30.3%)
-$534.78M(+69.6%)
Sep 2021
-
-$127.72M(-34.1%)
-$315.36M(-0.5%)
Jun 2021
-
-$193.84M(+56.1%)
-$316.87M(+32.9%)
Mar 2021
-
-$124.20M(-195.2%)
-$238.42M(+12.0%)
Dec 2020
-$312.23M
$130.40M(-200.9%)
-$212.87M(-52.6%)
Sep 2020
-
-$129.24M(+12.0%)
-$448.99M(+15.3%)
DateAnnualQuarterlyTTM
Jun 2020
-
-$115.39M(+17.0%)
-$389.56M(+15.4%)
Mar 2020
-
-$98.64M(-6.7%)
-$337.53M(+17.4%)
Dec 2019
-$298.83M(+139.1%)
-$105.72M(+51.5%)
-$287.42M(+31.3%)
Sep 2019
-
-$69.80M(+10.2%)
-$218.89M(+18.4%)
Jun 2019
-
-$63.35M(+30.5%)
-$184.89M(+52.1%)
Mar 2019
-
-$48.54M(+30.5%)
-$121.54M(+29.0%)
Dec 2018
-$124.99M(+146.9%)
-$37.20M(+3.9%)
-$94.23M(+65.2%)
Sep 2018
-
-$35.80M(+68.7%)
-$57.03M(+26.9%)
Mar 2018
-
-$21.23M(+83.2%)
-$44.95M(+14.4%)
Dec 2017
-$50.63M(+86.7%)
-
-
Sep 2017
-
-$11.59M(-4.5%)
-$39.30M(+12.5%)
Jun 2017
-
-$12.13M(+34.0%)
-$34.94M(+53.2%)
Mar 2017
-
-$9.05M(+38.8%)
-$22.81M(+65.8%)
Dec 2016
-$27.12M(+35.0%)
-$6.52M(-9.9%)
-$13.76M(-3.1%)
Sep 2016
-
-$7.23M(+3.9%)
-$14.20M(+17.1%)
Dec 2015
-$20.09M(+78.0%)
-$6.96M(+35.0%)
-$12.12M(+50.2%)
Sep 2015
-
-$5.16M(+77.0%)
-$8.07M(+44.6%)
Dec 2014
-$11.29M(+180.6%)
-$2.91M(+9.3%)
-$5.58M(+109.3%)
Sep 2014
-
-$2.67M
-$2.67M
Dec 2013
-$4.02M
-
-

FAQ

  • What is Apellis Pharmaceuticals, Inc. annual EBITDA?
  • What is the all time high annual EBITDA for Apellis Pharmaceuticals, Inc.?
  • What is Apellis Pharmaceuticals, Inc. annual EBITDA year-on-year change?
  • What is Apellis Pharmaceuticals, Inc. quarterly EBITDA?
  • What is the all time high quarterly EBITDA for Apellis Pharmaceuticals, Inc.?
  • What is Apellis Pharmaceuticals, Inc. quarterly EBITDA year-on-year change?
  • What is Apellis Pharmaceuticals, Inc. TTM EBITDA?
  • What is the all time high TTM EBITDA for Apellis Pharmaceuticals, Inc.?
  • What is Apellis Pharmaceuticals, Inc. TTM EBITDA year-on-year change?

What is Apellis Pharmaceuticals, Inc. annual EBITDA?

The current annual EBITDA of APLS is -$154.53M

What is the all time high annual EBITDA for Apellis Pharmaceuticals, Inc.?

Apellis Pharmaceuticals, Inc. all-time high annual EBITDA is -$4.02M

What is Apellis Pharmaceuticals, Inc. annual EBITDA year-on-year change?

Over the past year, APLS annual EBITDA has changed by +$340.60M (+68.79%)

What is Apellis Pharmaceuticals, Inc. quarterly EBITDA?

The current quarterly EBITDA of APLS is -$32.84M

What is the all time high quarterly EBITDA for Apellis Pharmaceuticals, Inc.?

Apellis Pharmaceuticals, Inc. all-time high quarterly EBITDA is $130.40M

What is Apellis Pharmaceuticals, Inc. quarterly EBITDA year-on-year change?

Over the past year, APLS quarterly EBITDA has changed by -$3.85M (-13.26%)

What is Apellis Pharmaceuticals, Inc. TTM EBITDA?

The current TTM EBITDA of APLS is -$188.26M

What is the all time high TTM EBITDA for Apellis Pharmaceuticals, Inc.?

Apellis Pharmaceuticals, Inc. all-time high TTM EBITDA is -$2.67M

What is Apellis Pharmaceuticals, Inc. TTM EBITDA year-on-year change?

Over the past year, APLS TTM EBITDA has changed by +$123.08M (+39.53%)
On this page